Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis
- 20 April 2015
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 112 (18), 5803-5808
- https://doi.org/10.1073/pnas.1502400112
Abstract
We have shown that cellular inhibitor of apoptosis proteins (cIAPs) impair clearance of hepatitis B virus (HBV) infection by preventing TNF-mediated killing/death of infected cells. A key question, with profound therapeutic implications, is whether this finding can be translated to the development of drugs that promote elimination of infected cells. Drug inhibitors of cIAPs were developed as cancer therapeutics to promote TNF-mediated tumor killing. These drugs are also known as Smac mimetics, because they mimic the action of the endogenous protein Smac/Diablo that antagonizes cIAP function. Here, we show using an immunocompetent mouse model of chronic HBV infection that birinapant and other Smac mimetics are able to rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hepatocytes containing HBV core antigen. The efficacy of Smac mimetics in treating HBV infection is dependent on their chemistry, host CD4+ T cells, and TNF. Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA production in HBV-infected animals. These results indicate that birinapant and other Smac mimetics may have efficacy in treating HBV infection and perhaps, other intracellular infections. Significance Current antiviral treatments for chronic hepatitis B virus (HBV) infection are effective in suppressing production of virus, but they have poor efficacy in promoting the elimination of infection. Hence, most patients with chronic HBV infection are maintained on antiviral therapies indefinitely. There is much interest in identifying treatments that promote the clearance of infected hepatocytes, thus purging the HBV DNA reservoir in the liver. Here, we show that the clinical-stage drug birinapant, which antagonizes host cell inhibitor of apoptosis proteins (cIAPs), preferentially promotes the killing of HBV-infected hepatocytes in a mouse model of HBV. Therefore, birinapant and other antagonists of cIAPs may be efficacious in the treatment of chronic HBV infection and may promote elimination of virus.Keywords
Funding Information
- Department of Health, Australian Government | National Health and Medical Research Council (637350, 1006592, 1044449, 1065626)
- Department of Health, Australian Government | National Health and Medical Research Council (541902)
- Department of Industry, Innovation, Science, Research and Tertiary Education, Australian Government | Australian Research Council (FT1301000166)
This publication has 24 references indexed in Scilit:
- Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft ModelsMolecular Cancer Therapeutics, 2014
- Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon SignalingScience, 2013
- Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV InfectionScience, 2013
- T-cell responses in hepatitis B and C virus infection: similarities and differencesEmerging Microbes & Infections, 2013
- Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanismBreast Cancer Research and Treatment, 2012
- Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapyAnnals Of The Rheumatic Diseases, 2011
- IAP Antagonists Target cIAP1 to Induce TNFα-Dependent ApoptosisCell, 2007
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and successProceedings of the National Academy of Sciences of the United States of America, 2003
- SingleH2Kb, H2Db and doubleH2KbDb knockout mice: peripheral CD8+ T cell repertoire and antilymphocytic choriomeningitis virus cytolytic responsesEuropean Journal of Immunology, 1999